ADIPOQ and myeloid sarcoma: Table 1 illustrates the characteristics of all the included studies in this first meta-analysis. The 16 studies9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 contained 4,113 MS cases and 3,637 healthy controls. The distributions of the genotype frequencies of the controls were all consistent with the HWE (all P > 0.05). The serum adiponectin levels presented in Table 1 shows that the concentration of adiponectin is lower in MS patients and higher in controls (P = 0.0016).